ATE424842T1 - Proteine der bcl-2-familie und fragmente davon, und ihre verwendung bei krebspatienten - Google Patents

Proteine der bcl-2-familie und fragmente davon, und ihre verwendung bei krebspatienten

Info

Publication number
ATE424842T1
ATE424842T1 AT04797460T AT04797460T ATE424842T1 AT E424842 T1 ATE424842 T1 AT E424842T1 AT 04797460 T AT04797460 T AT 04797460T AT 04797460 T AT04797460 T AT 04797460T AT E424842 T1 ATE424842 T1 AT E424842T1
Authority
AT
Austria
Prior art keywords
fragments
bcl
cancer patients
family proteins
proteins
Prior art date
Application number
AT04797460T
Other languages
English (en)
Inventor
Eivind Straten
Mads Andersen
Original Assignee
Survac Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Survac Aps filed Critical Survac Aps
Application granted granted Critical
Publication of ATE424842T1 publication Critical patent/ATE424842T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT04797460T 2003-11-19 2004-11-18 Proteine der bcl-2-familie und fragmente davon, und ihre verwendung bei krebspatienten ATE424842T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52311903P 2003-11-19 2003-11-19
DKPA200301716 2003-11-19

Publications (1)

Publication Number Publication Date
ATE424842T1 true ATE424842T1 (de) 2009-03-15

Family

ID=39149116

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04797460T ATE424842T1 (de) 2003-11-19 2004-11-18 Proteine der bcl-2-familie und fragmente davon, und ihre verwendung bei krebspatienten

Country Status (17)

Country Link
US (1) US7842294B2 (de)
EP (2) EP1691824B1 (de)
JP (2) JP4926714B2 (de)
KR (2) KR101284237B1 (de)
CN (1) CN1921878B (de)
AT (1) ATE424842T1 (de)
AU (1) AU2004290866B2 (de)
CA (1) CA2546794C (de)
DE (1) DE602004019965D1 (de)
DK (2) DK1691824T3 (de)
ES (2) ES2436429T3 (de)
MX (1) MXPA06005738A (de)
PL (2) PL2087904T3 (de)
PT (1) PT1691824E (de)
RU (1) RU2367468C2 (de)
WO (1) WO2005049073A2 (de)
ZA (1) ZA200604866B (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7892559B2 (en) * 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
ES2633389T3 (es) * 2003-01-30 2017-09-21 Survac Aps Péptidos derivados de survivina y uso de los mismos
WO2006034334A2 (en) 2004-09-21 2006-03-30 University Of Pittsburgh Of The Commonwealth System Of Higher Education Peptide analogs capable of enhancing stimulation of a glioma-specific ctl response
JP2008517070A (ja) * 2004-10-19 2008-05-22 マサチューセッツ インスティテュート オブ テクノロジー 自己組織化式の可撓性かつ軽量のリチウム電池のためのウイルス骨格
AU2011203535B2 (en) * 2005-02-04 2012-10-11 Survac Aps Survivin peptide vaccine
CN103143004A (zh) * 2005-02-04 2013-06-12 萨瓦克公司 存活蛋白肽疫苗
US20100317577A1 (en) * 2005-09-09 2010-12-16 Department Of Health And Human Services Methods and Compositions for Inhibiting Cell Death or Enhacing Cell Proliferation
EP2361930A3 (de) 2007-03-26 2011-10-26 Dako Denmark A/S Multimere von peptide-mhc komplexen und deren verwendung in borrelia infektionskrankheiten
EP3620465B1 (de) * 2007-07-03 2025-02-19 Dako Denmark A/S Verbesserte verfahren zur herstellung, markierung und verwendung von mhc-multimeren
US10611818B2 (en) 2007-09-27 2020-04-07 Agilent Technologies, Inc. MHC multimers in tuberculosis diagnostics, vaccine and therapeutics
EP2254592B1 (de) * 2008-02-28 2019-06-05 Dako Denmark A/S Mhc-multimere in borrelia-diagnostika und erkrankungen
DK2254592T3 (da) 2008-02-28 2019-09-09 Dako Denmark As MHC-multimerer til Borrelia-diagnostik og sygdom
EP2285832B1 (de) 2008-05-16 2020-08-26 Taiga Biotechnologies, Inc. Antikörper und herstellungsverfahren dafür
WO2010009350A2 (en) * 2008-07-16 2010-01-21 Burnham Institute For Medical Research Compositions and methods for modulating nod-like receptor activity and uses thereof
US10722562B2 (en) 2008-07-23 2020-07-28 Immudex Aps Combinatorial analysis and repair
EP2318435B1 (de) 2008-08-28 2015-12-23 Taiga Biotechnologies, Inc. Myc-modulatoren, verfahren zu ihrer verwendung und verfahren zur identifikation von mitteln zur myc-modulierung
GB0817244D0 (en) 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
WO2010037395A2 (en) * 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
WO2010037397A1 (en) * 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cmv immune monitoring
WO2010037402A1 (en) 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
WO2010045573A2 (en) * 2008-10-17 2010-04-22 University Of Miami Tumor vaccine
EP3444333A1 (de) * 2009-10-22 2019-02-20 Thomas Jefferson University Zellbasierte antikrebszusammensetzungen sowie verfahren zur herstellung und verwendung davon
WO2011111392A1 (en) * 2010-03-11 2011-09-15 Oncotherapy Science, Inc. Hjurp peptides and vaccines including the same
EP2608799B1 (de) * 2010-08-24 2018-12-12 University of Pittsburgh - Of the Commonwealth System of Higher Education Impfstoffe gegen hirntumore auf interleukin-13-rezeptor-alpha 2-peptid-basis
DK3536334T3 (da) 2012-05-16 2021-09-13 Stemline Therapeutics Inc Cancer stamcelle målrettede cancer vacciner
JP6285930B2 (ja) * 2012-07-20 2018-02-28 タイガ バイオテクノロジーズ，インク． 造血コンパートメントの再構築及び自家再構築の増進
CN105228640B (zh) * 2013-02-26 2018-01-16 王荣福 Phf20和jmjd3组合物及其在肿瘤免疫治疗中的使用方法
RU2671897C2 (ru) * 2013-03-01 2018-11-07 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Способы получения из опухоли обогащенных популяций реактивных в отношении опухоли т-клеток
US9704181B2 (en) * 2014-05-06 2017-07-11 International Business Machines Corporation Real-time social group based bidding system
KR20190092472A (ko) 2016-12-02 2019-08-07 타이가 바이오테크놀로지스, 인코포레이티드 나노입자 제제
MA47367B1 (fr) * 2017-01-27 2023-06-28 Immatics Biotechnologies Gmbh Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers
IL299051A (en) * 2017-01-27 2023-02-01 Immatics Biotechnologies Gmbh New peptides and their combinations for immunotherapy against ovarian cancer and other cancers
EA201991444A1 (ru) 2017-01-27 2019-12-30 Имматикс Байотекнолоджиз Гмбх Новые пептиды и комбинации пептидов для применения в иммунотерапии рака яичника и других видов рака
KR20210086612A (ko) 2018-09-04 2021-07-08 트레오스 바이오 리미티드 펩타이드 백신
US12258373B2 (en) 2018-12-17 2025-03-25 Immudex Aps Panel comprising Borrelia MHC multimers
WO2020210231A1 (en) 2019-04-08 2020-10-15 Taiga Biotechnologies, Inc. Compositions and methods for the cry opreservation of immune cells
EP3969041A4 (de) 2019-05-14 2023-05-10 Taiga Biotechnologies, Inc. Zusammensetzungen und verfahren zur behandlung von t-zell-erschöpfung
CN113355432A (zh) * 2021-05-12 2021-09-07 甘肃农业大学 Bmf作为细胞凋亡标志物的应用
WO2022245249A1 (ru) * 2021-05-17 2022-11-24 федеральное государственное автономное образовательное учреждение высшего образования Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский университет) Пептидные соединения для индукции апоптоза в опухолевой клетке

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US5342774A (en) 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
ES2225824T3 (es) 1992-08-31 2005-03-16 Ludwig Institute For Cancer Research Nonapeptido aislado derivado del gen mage-3 y presentado por hla-a1, y sus usos.
US5470955A (en) 1993-02-02 1995-11-28 Dartmouth College Antibodies which specifically bind mcl-1 polypeptide
US5646008A (en) * 1993-06-22 1997-07-08 The Regent Of The University Of Michigan Vertebrate apoptosis gene: compositions and methods
US5700638A (en) * 1993-08-26 1997-12-23 Washington University Cell death regulator
GB9320597D0 (en) 1993-10-06 1993-11-24 Proteus Molecular Design Improvements in and realting to vaccines
US6096313A (en) 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
US5789201A (en) * 1996-02-23 1998-08-04 Cocensys, Inc. Genes coding for bcl-y a bcl-2 homologue
US6245523B1 (en) 1996-11-20 2001-06-12 Yale University Survivin, a protein that inhibits cellular apoptosis, and its modulation
WO1998058541A1 (en) * 1997-06-24 1998-12-30 Dana-Farber Cancer Institute, Inc. Modulation of apoptosis
AU3471200A (en) 1999-11-16 2001-05-30 Dartmouth College Mcl-1 gene regulatory elements and a pro-apoptotic mcl-1 variant
CA2390662A1 (en) * 1999-12-14 2001-06-21 The Burnham Institute Bcl-g polypeptides, encoding nucleic acids and methods of use
WO2002005835A2 (en) * 2000-07-17 2002-01-24 Washington University Modulation of apoptosis
WO2002072627A2 (en) * 2001-03-09 2002-09-19 Callistogen Ag Induction of anti-tumor cytotoxic t-lymphocytes in humans using peptide epitopes found by computer based algorithms for vaccination
US7892559B2 (en) * 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
PL1618130T3 (pl) 2003-04-11 2013-08-30 Survac Aps Szczepionka terapeutyczna przeciw nowotworom

Also Published As

Publication number Publication date
HK1101131A1 (en) 2007-10-12
CA2546794A1 (en) 2005-06-02
DK2087904T3 (da) 2013-12-02
DK1691824T3 (da) 2009-07-06
WO2005049073A3 (en) 2006-01-05
EP1691824B1 (de) 2009-03-11
KR20130026527A (ko) 2013-03-13
PL1691824T3 (pl) 2009-08-31
PT1691824E (pt) 2009-05-28
EP2087904B1 (de) 2013-08-28
MXPA06005738A (es) 2006-12-14
AU2004290866B2 (en) 2010-09-02
KR101216655B1 (ko) 2013-01-02
ES2323588T3 (es) 2009-07-21
JP2007511547A (ja) 2007-05-10
JP4926714B2 (ja) 2012-05-09
US20080050396A1 (en) 2008-02-28
JP2011246496A (ja) 2011-12-08
CN1921878A (zh) 2007-02-28
EP2087904A1 (de) 2009-08-12
DE602004019965D1 (de) 2009-04-23
JP5502823B2 (ja) 2014-05-28
EP1691824A2 (de) 2006-08-23
KR101284237B1 (ko) 2013-07-09
CN1921878B (zh) 2012-04-25
ZA200604866B (en) 2008-05-28
WO2005049073A2 (en) 2005-06-02
CA2546794C (en) 2013-09-17
AU2004290866A1 (en) 2005-06-02
US7842294B2 (en) 2010-11-30
ES2436429T3 (es) 2014-01-02
PL2087904T3 (pl) 2014-01-31
KR20060132622A (ko) 2006-12-21
RU2006121466A (ru) 2007-12-27
RU2367468C2 (ru) 2009-09-20

Similar Documents

Publication Publication Date Title
ATE424842T1 (de) Proteine der bcl-2-familie und fragmente davon, und ihre verwendung bei krebspatienten
ATE486087T1 (de) Fgf-5-bindende und geträgerte peptide
CA2523467C (en) Treatment of t-cell mediated diseases
CY1119127T1 (el) Επιτοποι σκληροστινης
CY1117387T1 (el) ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ Ν-11 ΔΙΑΣΠΑΣΜΕΝΟΥ β-ΑΜΥΛΟΕΙΔΟΥΣ, ΣΥΝΘΕΣΕΙΣ, ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ
DK1368060T3 (da) HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme
DE60032486D1 (de) Prion protein peptide und deren verwendung
DK1545613T3 (da) Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
NO20045521L (no) Diarylureaderivater anvendelige for behandling av proteinkinaseavhengige sykdommer
ATE549353T1 (de) Aktive varianten des il-18 bindenden proteins und dessen medizinische verwendungen
ATE551069T1 (de) Mucin-fusionspolypeptid-vakzine, zusammensetzungen und ihre verwendung
DE60230456D1 (de) Faktor-viii-polypeptide auf hohem expressionsnivea und verwendungsverfahren
DK2229440T3 (da) Rekombinante elastase-proteiner og fremgangsmåder til fremstilling og anvendelse deraf
MA27880A1 (fr) Derives de tetrahydrocarbazole et leur utilisation pharmaceutique
WO2007034489A3 (en) Immunogenic fragments of t-cell receptor constant domains and peptides derived therefrom
EA200801411A1 (ru) Новые адъюванты на основе конъюгатов и производных бис-ацилоксипропилцистеина и их применения в фармацевтических композициях
WO2006137938A3 (en) Antibody fragments for protection from pathogen infection and methods of use thereof
ATE543833T1 (de) Bmp-7-varianten-zusammensetzungen, verfahren und verwendungen
WO2001007479A3 (en) Fragments of cellular prion protein and methods useful in the diagnosis and treatment of prion diseases
DK1578772T3 (da) Cytokiner og cytokinreceptorer med reduceret immunogenicitet
EA200600314A1 (ru) Использование растворимого cd164 при воспалительных и/или аутоимунных нарушениях
ATE505538T1 (de) Dna-vektoren
DE60229924D1 (de) Fusionsproteine zur spezifisichen behandlung von krebs und autoimmunkrankheiten
CY1108761T1 (el) Απενεργοποιημενες κυτοκινες για ανοσοποιηση
WO2006110881A3 (en) Yersinia polypeptide vaccines, antibodies and immunomodulatory proteins

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1691824

Country of ref document: EP

EEIH Change in the person of patent owner